Yes, they could, and moreover, nwbo could potentially knock them out of the subtype for classical tumors as well -- the latter subtype was not labeled/classified in UCLA's earlier studies on DCVax-L.
That's why I still think there is a chance the FDA and the companies might, might be wise to determine where the therapies stand in terms of turf before they announce, but maybe that's completely unrealistic on my part.
It might be smarter for both to come out knowing where they overlap in potential sales, and where they do not.
It would be good for both companies to start 2nd generation cancer vaccine immunotherapy on the right foot.
News 
Market Data 
Discover 
AI
